Skip to content

PolyPeptide

Active
Public limited companyfounded 200620 yrs activeChaussée de Tubize 297, 1420 Braine-l'Alleud, BelgiumKBO/BCE: BE 0879.346.768
Summary

PolyPeptide has been active since 2006 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €96.61M and a net result of €-3.17M. Equity is growing by ~5.2% per year across the filed fiscal years. Its solvency ranks better than 41% of 85 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.6% (low).

Checked score

Score 2024
Axes · tick = 2022
Profitability39▼-34
Solvency61▼-11
Growth65▼-19
Track record100
Bankruptcy probability, 12 months
0.6% Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €2M at 30 days acceptable
Liquidity ample (current ratio 1.68 against 2.48 in 2022; short-term debt: 22.5% and cash: 0.1% of total assets), but 64.4% of the assets are financed with debt.
Credit check for your own amount and term

Open the credit simulator : see how the verdict changes with amount, term and advance.

Signals

Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Multiple establishment units
Several establishment units mean more fixed costs, and such companies fail more often than a company with one establishment.
KBO · establishment units
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 20 years 0 30 y
lowers risk · Lower-risk legal form
Companies with this legal form statistically fail less often than a BV.
KBO · legal form
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies more bankruptcies →
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2024
Solvency, return and age of the figures
Solvency
35.6%
Return on assets
-1.2%
Age of the figures
21 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 03-06-2025, 58 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
not confirmed
2024
58 d early
2023
64 d early
2022
62 d early
2021
52 d early
2020
65 d early
2019
57 d early
← before the deadline after the deadline →
Checked, nothing found (1)
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

On 14 February 2006, PolyPeptide was incorporated.1 The capital was increased 2 times between 2007 and 2013, most recently to EUR 104 million.23 The name was changed to PolyPeptide in 2017.4 Polypeptide Laboratories Holding (PPL) AB has served as sole director of the company since 2023.5 Revenue went from EUR 49 million in 2018 to EUR 128 million in 2024 and headcount from 238 to 468 full-time equivalents.6

  1. 1Crossroads Bank for Enterprises
  2. 2Belgian State Gazette, 29-08-2007
  3. 3Belgian State Gazette, 24-01-2013
  4. 4Belgian State Gazette, 03-02-2017
  5. 5Belgian State Gazette, 13-06-2023
  6. 6National Bank, annual accounts 2018 and 2024

Go further with this company

Is this your company? See how customers and banks see it.

Financials · fiscal year 2024, full schema

Turnover
€127.94M▲ 29.7%
2022 · €98.66M
EBIT margin
4.0%▼ 3.1pp
2022 · 7.1%
Net result
€-3.17M
2022 · €5.45M
Working capital
€41.73M▼ 32.1%
2022 · €61.49M
Trend over the years

Click a name to add, emphasise or remove a line.

Every figure with its change against the fiscal year before
favourable unfavourable
Line20192020202120222024
Turnover€52.71M▲ 7.0%€53.84M▲ 2.1%€64.08M▲ 19.0%€98.66M▲ 54.0%€127.94M-
Operating result€5.53M▲ 0.6%€5.12M▼ 7.5%€5.86M▲ 14.4%€6.97M▲ 19.0%€5.09M-
Net result€4.76M▼ 6.3%€4.55M▼ 4.5%€4.90M▲ 7.8%€5.45M▲ 11.1%€-3.17M-
EBIT margin10.5%▼ 0.7pp9.5%▼ 1.0pp9.1%▼ 0.4pp7.1%▼ 2.1pp4.0%-
Equity€83.40M▲ 6.0%€87.89M▲ 5.4%€92.75M▲ 5.5%€98.14M▲ 5.8%€96.61M-
Total assets€108.90M▲ 9.3%€110.31M▲ 1.3%€145.79M▲ 32.2%€209.65M▲ 43.8%€271.07M-
Debt€24.70M▲ 23.7%€21.88M▼ 11.4%€52.56M▲ 140%€110.39M▲ 110%€173.51M-
Working capital€43.28M▲ 35.3%€36.25M▼ 16.2%€48.66M▲ 34.2%€61.49M▲ 26.4%€41.73M-
Staff (FTE)240.1▲ 1.0%265.7▲ 10.7%317.2▲ 19.4%394▲ 24.2%468.1-
Result per fiscal year
Operating resultNet result
€-5.00M€0€5.00MOperating result 2019: €5.53M€5.53MNet result 2019: €4.76M€4.76MOperating result 2020: €5.12M€5.12MNet result 2020: €4.55M€4.55MOperating result 2021: €5.86M€5.86MNet result 2021: €4.90M€4.90MOperating result 2022: €6.97M€6.97MNet result 2022: €5.45M€5.45MOperating result 2024: €5.09M€5.09MNet result 2024: €-3.17M€-3.17M20192020202120222024€-5M€0€5MOperating result 2021: €5.86M€5.9MNet result 2021: €4.90M€4.9MOperating result 2022: €6.97M€7MNet result 2022: €5.45M€5.4MOperating result 2024: €5.09M€5.1MNet result 2024: €-3.17M€-3.2M202120222024
The operating result is €5.09M in 2024, compared with €6.97M in 2022. Comparable figures for the intervening years are unavailable.
Balance-sheet composition
2024 in colour, 2022 as the grey bar beneath
Assets €271.07M
Fixed assets €168.28M ▲ 57.9%
Current assets €102.79M ▼ 0.3%
Equity and liabilities €271.07M
Equity €96.61M ▼ 1.6%
Provisions €947k ▼ 14.9%
Debt €173.51M ▲ 57.2%
Debt's share of the balance-sheet total rises from 52.7% to 64.0%. Equity is lower and debt is higher.
Key figures and ratios
2024 value · change against 2022
EBITDA
€11.11M▼
2022 · €13.24M
Cash flow
€2.85M▼
2022 · €11.72M
Current ratio
1.68▼
2022 · 2.48
Quick ratio
0.53▼
2022 · 0.58
Debt to equity
1.80▲
2022 · 1.12
ROE
-3.3%▼
2022 · 5.5%
ROA
-1.2%▼
2022 · 2.6%
Interest coverage
1.65▼
2022 · 11.06
Debt ≤ 1 year
€61.06M▲
2022 · €41.59M
Debt > 1 year
€112.24M▲
2022 · €68.28M
Income taxes
€435k▼
2022 · €534k
Staff costs
€51.15M▲
2022 · €39.48M
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
Filed annual accounts As filed with the NBB · 2024 against 2022 · 83 lines
Balance sheet Code20222024
Assets
Total assets20/58€209.65M€271.07M▲
Fixed assets21/28€106.57M€168.28M▲
Intangible fixed assets21€2.70M€174k▼
Tangible fixed assets22/27€103.87M€168.10M▲
Land and buildings22€12.93M€25.91M▲
Plant, machinery and equipment23€39.14M€91.41M▲
Furniture and vehicles24€1.80M€6.85M▲
Leasing and similar rights25€1.79M€3.78M▲
Assets under construction and advance payments27€48.20M€40.15M▼
Current assets29/58€103.08M€102.79M▼
Stocks and contracts in progress3€79.08M€70.49M▼
Stocks30/36€79.08M€70.49M▼
Raw materials and consumables30/31€36.00M€45.16M▲
Work in progress32€27.13M€21.44M▼
Finished goods33€15.95M€3.88M▼
Amounts receivable within one year40/41€21.67M€31.81M▲
Trade receivables40€21.62M€31.28M▲
Other amounts receivable41€45k€533k▲
Cash at bank and in hand54/58€2.06M€307k▼
Deferred charges and accrued income490/1€280k€180k▼
Equity and liabilities
Total equity and liabilities10/49€209.65M€271.07M▲
Equity10/15€98.14M€96.61M▼
Contributions10/11€40.00M€40.00M=
Capital10€40.00M€40.00M=
Issued capital100€40.00M€40.00M=
Reserves13€2.89M€2.98M▲
Non-distributable reserves130/1€2.89M€2.98M▲
Legal reserve130€2.89M€2.98M▲
Profit (loss) carried forward14€54.91M€53.39M▼
Investment grants15€342k€241k▼
Provisions and deferred taxes16€1.11M€947k▼
Provisions for liabilities and charges160/5€1.11M€947k▼
Pensions and similar obligations160€1.04M€877k▼
Other liabilities and charges164/5€75k€70k▼
Amounts payable17/49€110.39M€173.51M▲
Amounts payable after more than one year17€68.28M€112.24M▲
Financial debts170/4€68.28M€112.24M▲
Leasing and similar obligations172€1.05M€2.10M▲
Other loans174€67.23M€110.14M▲
Amounts payable within one year42/48€41.59M€61.06M▲
Current portion of amounts payable after more than one year42€386k€857k▲
Trade debts44€35.55M€50.91M▲
Suppliers440/4€35.55M€50.91M▲
Taxes, remuneration and social security45€5.62M€9.28M▲
Taxes450/3€905k€3.56M▲
Remuneration and social security454/9€4.71M€5.72M▲
Other amounts payable47/48€36k€8k▼
Accrued charges and deferred income492/3€527k€216k▼
Income statement Code20222024
Operating income70/76A€108.65M€137.77M▲
Turnover70€98.66M€127.94M▲
Change in stocks of work in progress, finished goods and contracts in progress71€5.84M€2.06M▼
Own construction capitalised72€618k€2.76M▲
Other operating income74€3.45M€5.02M▲
Non-recurring operating income76A€82k-
Operating charges60/66A€101.68M€132.69M▲
Goods for resale, raw materials and consumables60€24.08M€28.46M▲
Purchases600/8€36.29M€32.51M▼
Change in stocks: decrease (increase)609€-12.21M€-4.04M▲
Services and other goods61€30.06M€46.48M▲
Remuneration, social security and pensions62€39.48M€51.15M▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€6.27M€6.02M▼
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€673k€-1.77M▼
Provisions for liabilities and charges: additions (uses and reversals)635/8€630k€512k▼
Other operating charges640/8€416k€402k▼
Non-recurring operating charges66A€69k€1.43M▲
Operating profit (loss)9901€6.97M€5.09M▼
Financial income75/76B€2.25M€685k▼
Recurring financial income75€2.25M€685k▼
Other financial income752/9€2.25M€685k▼
Financial charges65/66B€3.25M€8.50M▲
Recurring financial charges65€3.25M€8.50M▲
Debt charges650€1.20M€6.73M▲
Other financial charges652/9€2.05M€1.77M▼
Profit (loss) for the period before taxes9903€5.98M€-2.73M▼
Income taxes67/77€534k€435k▼
Taxes670/3€534k€435k▼
Profit (loss) for the period9904€5.45M€-3.17M▼
Profit (loss) for the period to be appropriated9905€5.45M€-3.17M▼
Appropriation of the result
Profit (loss) to be appropriated9906€55.18M€53.39M▼
Profit (loss) brought forward from the previous period14P€49.74M€56.55M▲
Transfer to equity691/2€272k-
To the legal reserve6920€272k-
Social balance
Average headcount (FTE)9087394.0468.1▲

The notes to these accounts (85 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20192020202120222024Change
Operating income70/76A--€83.08M€108.65M€137.77M-
Turnover70€52.71M€53.84M€64.08M€98.66M€127.94M-
Change in stocks of work in progress, finished goods and contracts in progress71--€15.12M€5.84M€2.06M-
Own construction capitalised72--€994k€618k€2.76M-
Other operating income74--€2.85M€3.45M€5.02M-
Non-recurring operating income76A--€38k€82k--
Operating charges60/66A--€77.22M€101.68M€132.69M-
Goods for resale, raw materials and consumables60--€17.18M€24.08M€28.46M-
Purchases600/8--€24.60M€36.29M€32.51M-
Change in stocks: decrease (increase)609--€-7.42M€-12.21M€-4.04M-
Services and other goods61--€21.67M€30.06M€46.48M-
Remuneration, social security and pensions62--€29.81M€39.48M€51.15M-
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€4.74M€5.11M€5.45M€6.27M€6.02M-
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4--€2.95M€673k€-1.77M-
Provisions for liabilities and charges: additions (uses and reversals)635/8--€-53k€630k€512k-
Other operating charges640/8--€229k€416k€402k-
Non-recurring operating charges66A--€216€69k€1.43M-
Operating profit (loss)9901€5.53M€5.12M€5.86M€6.97M€5.09M-
Financial income75/76B--€496k€2.25M€685k-
Recurring financial income75€94k€242k€496k€2.25M€685k-
Other financial income752/9--€496k€2.25M€685k-
Financial charges65/66B--€1.02M€3.25M€8.50M-
Recurring financial charges65€268k€431k€1.02M€3.25M€8.50M-
Debt charges650€238k€148k€236k€1.20M€6.73M-
Other financial charges652/9--€782k€2.05M€1.77M-
Profit (loss) for the period before taxes9903€5.36M€4.93M€5.34M€5.98M€-2.73M-
Income taxes67/77€598k€381k€432k€534k€435k-
Taxes670/3--€432k€534k€435k-
Profit (loss) for the period9904€4.76M€4.55M€4.90M€5.45M€-3.17M-
Profit (loss) for the period to be appropriated9905€4.76M€4.55M€4.90M€5.45M€-3.17M-
Line20192020202120222024Change
Assets
Total assets20/58€108.90M€110.31M€145.79M€209.65M€271.07M-
Fixed assets21/28€51.97M€59.28M€74.87M€106.57M€168.28M-
Intangible fixed assets21€5.11M€4.30M€3.50M€2.70M€174k-
Tangible fixed assets22/27€46.86M€54.97M€71.36M€103.87M€168.10M-
Land and buildings22--€11.38M€12.93M€25.91M-
Plant, machinery and equipment23--€27.64M€39.14M€91.41M-
Furniture and vehicles24--€2.07M€1.80M€6.85M-
Leasing and similar rights25--€1.20M€1.79M€3.78M-
Assets under construction and advance payments27--€29.08M€48.20M€40.15M-
Financial fixed assets28€5k€5k€5k---
Other financial fixed assets284/8--€5k---
Amounts receivable and cash guarantees285/8--€5k---
Current assets29/58€56.93M€51.03M€70.92M€103.08M€102.79M-
Stocks and contracts in progress3€32.28M€42.10M€61.70M€79.08M€70.49M-
Stocks30/36--€61.70M€79.08M€70.49M-
Raw materials and consumables30/31--€24.71M€36.00M€45.16M-
Work in progress32--€29.49M€27.13M€21.44M-
Finished goods33--€7.50M€15.95M€3.88M-
Amounts receivable within one year40/41€22.21M€7.68M€4.67M€21.67M€31.81M-
Trade receivables40--€4.10M€21.62M€31.28M-
Other amounts receivable41--€579k€45k€533k-
Cash at bank and in hand54/58€2.42M€1.19M€4.30M€2.06M€307k-
Deferred charges and accrued income490/1--€248k€280k€180k-
Equity and liabilities
Total equity and liabilities10/49€108.90M€110.31M€145.79M€209.65M€271.07M-
Equity10/15€83.40M€87.89M€92.75M€98.14M€96.61M-
Contributions10/11€40.00M€40.00M€40.00M€40.00M€40.00M-
Capital10--€40.00M€40.00M€40.00M-
Issued capital100--€40.00M€40.00M€40.00M-
Reserves13€2.15M€2.37M€2.62M€2.89M€2.98M-
Non-distributable reserves130/1--€2.62M€2.89M€2.98M-
Legal reserve130--€2.62M€2.89M€2.98M-
Profit (loss) carried forward14€40.76M€45.08M€49.74M€54.91M€53.39M-
Investment grants15--€393k€342k€241k-
Provisions and deferred taxes16€802k€536k€483k€1.11M€947k-
Provisions for liabilities and charges160/5--€483k€1.11M€947k-
Pensions and similar obligations160--€390k€1.04M€877k-
Other liabilities and charges164/5--€94k€75k€70k-
Amounts payable17/49€24.70M€21.88M€52.56M€110.39M€173.51M-
Amounts payable after more than one year17€10.87M€6.87M€28.20M€68.28M€112.24M-
Financial debts170/4--€28.20M€68.28M€112.24M-
Leasing and similar obligations172--€725k€1.05M€2.10M-
Other loans174--€27.47M€67.23M€110.14M-
Amounts payable within one year42/48€13.65M€14.78M€22.27M€41.59M€61.06M-
Current portion of amounts payable after more than one year42--€217k€386k€857k-
Trade debts44€8.51M€10.42M€16.92M€35.55M€50.91M-
Suppliers440/4--€16.92M€35.55M€50.91M-
Taxes, remuneration and social security45--€3.60M€5.62M€9.28M-
Taxes450/3--€5k€905k€3.56M-
Remuneration and social security454/9--€3.59M€4.71M€5.72M-
Other amounts payable47/48--€1.54M€36k€8k-
Accrued charges and deferred income492/3--€2.10M€527k€216k-
Line20192020202120222024Change
Profit (loss) for the period9904€4.76M€4.55M€4.90M€5.45M€-3.17M-
+ Depreciation and write-downs630€4.74M€5.11M€5.45M€6.27M€6.02M-
Operating cash flow (approximation)€9.50M€9.66M€10.35M€11.72M€2.85M-
Investment in fixed assets (approximation)-€-12.42M€-21.05M€-37.97M--
Change in cash-€-1.24M€3.11M€-2.24M--

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

2025
18-11
State Gazette act Permanent representative: Raoul BERNHARDT
2 facts ▸
  • General meeting, 30/09/2025
  • Permanent representative, Raoul BERNHARDT
03-06
NBB filing Annual accounts filed
fiscal year 2024 · full schema
2024
31-12
Financial Weakest financial yearnet €-3.17M
Net result drops to €-3.17M, the lowest in the series.
18-06
State Gazette act Appointment: BDO Réviseurs d'Entreprises SRL (statutory auditor)
Permanent representative: Rodrigo ABELS3 facts ▸
  • General meeting, 21/05/2024
  • Auditor appointment, BDO Réviseurs d'Entreprises SRL (statutory auditor)
  • Permanent representative, Rodrigo ABELS
28-05
NBB filing Annual accounts filed
fiscal year 2023 · full schema
02-04
State Gazette act Resignations & appointments
Power of attorney2 facts ▸
  • Board meeting, 14/03/2024
  • Power of attorney, El Djouhar Rekai
2023
13-06
State Gazette act Resignations: Vincenzo MANCUSO, Jens FRICKE and Jan Fuhr MILLER
Appointment: PolyPeptide Laboratories Holding (PPL) AB (sole director) · Permanent representative: Jens FRICKE · Mandate compensation10 facts ▸
  • General meeting, 16/05/2023
  • Director resignation, Vincenzo MANCUSO (director)
  • Director resignation, Vincenzo MANCUSO (managing director and daily management delegate)
  • Director resignation, Jens FRICKE (director)
  • Director resignation, Jan Fuhr MILLER (director)
  • Director appointment, PolyPeptide Laboratories Holding (PPL) AB (sole director)
  • Permanent representative, Jens FRICKE
  • Mandate compensation, PolyPeptide Laboratories Holding (PPL) AB
  • Board meeting, 23/05/2023
  • Power of attorney, Ei Djouhar Rekal
30-05
NBB filing Annual accounts filed
fiscal year 2022 · full schema
23-03
State Gazette act Resignation: Raymond DE VRÉ (director)
Appointments: Jens FRICKE (director) and MANCUSO Vincenzo (managing director) · Mandate compensation6 facts ▸
  • General meeting, 02/03/2023
  • Board meeting, 02/03/2023
  • Director resignation, Raymond DE VRÉ (director)
  • Director appointment, Jens FRICKE (director)
  • Mandate compensation, Jens FRICKE
  • Director appointment, MANCUSO Vincenzo (managing director)
2022
31-12
Financial Highest result since 2018net €5.45M ▲11.1%
Operating result €6.97M, net result €5.45M, both a record.
28-12
State Gazette act Resignation: Daniel LASANOW (director)
Appointment: Jan Fuhr MILLER (director) · Director discharge · Mandate compensation5 facts ▸
  • General meeting, 8 décembre 2022
  • Director resignation, Daniel LASANOW (director)
  • Director discharge, Daniel LASANOW (director)
  • Director appointment, Jan Fuhr MILLER (director)
  • Mandate compensation, Jan Fuhr MILLER
14-06
State Gazette act Reappointment: Daniel LASANOW (director)
Mandate compensation3 facts ▸
  • General meeting, 17/05/2022
  • Director reappointment, Daniel LASANOW (director)
  • Mandate compensation, Daniel LASANOW
Show earlier events
09-06
NBB filing Annual accounts filed
fiscal year 2021 · full schema
2021
29-12
State Gazette act Statutes amendment
Capital3 facts ▸
  • General meeting, 16/12/2021
  • Statutes amendment
  • Capital, €40.000.000
20-12
State Gazette act Resignations: Jane Salik, Jan Fuhr Miller and 2 others
Appointments: Raymond De Vré (director) and Vincenzo Mancuso (director) · Mandate compensation · Power of attorney16 facts ▸
  • General meeting, 30/11/2021
  • Board meeting, 30/11/2021
  • Director resignation, Jane Salik (director)
  • Director resignation, Jan Fuhr Miller (director)
  • Director resignation, Lars-Göran Peter (Peter) Nilsson (director)
  • Director appointment, Raymond De Vré (director)
  • Director appointment, Vincenzo Mancuso (director)
  • Mandate compensation, Raymond De Vré
  • Mandate compensation, Vincenzo Mancuso
  • Power of attorney, Deloitte Legal - Lawyers
  • Power of attorney, Hanna Soininen
  • Power of attorney, Benoit Massez
  • +4 further facts in this act
31-08
State Gazette act Appointment: BDO Réviseurs d'Entreprises SRL (statutory auditor)
Power of attorney3 facts ▸
  • General meeting, 18/05/2021
  • Auditor appointment, BDO Réviseurs d'Entreprises SRL (statutory auditor)
  • Power of attorney, Gauthier DAVIGNON
27-05
NBB filing Annual accounts filed
fiscal year 2020 · full schema
2020
04-06
NBB filing Annual accounts filed
fiscal year 2019 · full schema
26-03
State Gazette act Resignations & appointments
Power of attorney4 facts ▸
  • Board meeting, 06/02/2020
  • Power of attorney, Serge Doris
  • Power of attorney, Hanna Soininen
  • Power of attorney, Hanna Soininen
03-02
State Gazette act Permanent representative: Rodrigo Abels
1 fact ▸
  • Permanent representative, Rodrigo Abels (représentant du commissaire)
2019
18-07
NBB filing Annual accounts filed
fiscal year 2018 · full schema
26-06
State Gazette act Appointments: Vincenzo Mancuso (personne chargée de la gestion journalière et directeur général) and El Djouhar Alexandra Rekai (personne chargée de la gestion journalière et directeur général adjoint)
3 facts ▸
  • Board meeting, 16/04/2019
  • Director appointment, Vincenzo Mancuso (personne chargée de la gestion journalière et directeur général)
  • Director appointment, El Djouhar Alexandra Rekai (personne chargée de la gestion journalière et directeur général adjoint)
2018
25-09
State Gazette act Resignations: Christian Cromlin (personne chargée de la gestion journalière et directeur général) and Alain Marlier (personne chargée de la gestion journalière et directeur général adjoint)
Power of attorney17 facts ▸
  • Board meeting, 27/06/2018
  • Director resignation, Christian Cromlin (personne chargée de la gestion journalière et directeur général)
  • Director resignation, Alain Marlier (personne chargée de la gestion journalière et directeur général adjoint)
  • Power of attorney, El Djouhar Alexandra Rekai
  • Power of attorney, Geneviève De Bue
  • Power of attorney, Serge Doris
  • Power of attorney, Olivier Gaziaux
  • Power of attorney, Benoit Massez
  • Power of attorney, El Djouhar Alexandra Rekai
  • Power of attorney, Geneviève De Bue
  • Power of attorney, Serge Doris
  • Power of attorney, Olivier Gaziaux
  • +5 further facts in this act
26-07
State Gazette act Appointments: KPMG Réviseurs d'Entreprises SC SCRL (statutory auditor) and BDO Réviseurs d'Entreprises SC SCRL (statutory auditor)
Power of attorney6 facts ▸
  • General meeting, 15-05-2018
  • Auditor appointment, KPMG Réviseurs d'Entreprises SC SCRL (statutory auditor)
  • Auditor appointment, BDO Réviseurs d'Entreprises SC SCRL (statutory auditor)
  • Power of attorney, Patrick VAN EYCK
  • Power of attorney, Régis PANISI
  • Power of attorney, Marcos LAMIN BUSSCHOTS
25-06
NBB filing Annual accounts filed
fiscal year 2017 · full schema
2017
15-12
State Gazette act Resignations: Frédérique Marie Vogeleisen (personne chargée de la gestion journalière et directeur général) and Bert Vanroye (personne chargée de la gestion journalière et directeur général adjoint)
Appointments: Christian Cromlin (personne chargée de la gestion journalière et directeur général) and Alain Marlier (personne chargée de la gestion journalière et directeur général adjoint) · Power of attorney13 facts ▸
  • Board meeting, 14/11/2017
  • Director resignation, Frédérique Marie Vogeleisen (personne chargée de la gestion journalière et directeur général)
  • Director resignation, Bert Vanroye (personne chargée de la gestion journalière et directeur général adjoint)
  • Power of attorney, El Djouhar Alexandra Rekaï
  • Power of attorney, Geneviève De Bue
  • Power of attorney, Mireille Leclercq
  • Power of attorney, Serge Doris
  • Director appointment, Christian Cromlin (personne chargée de la gestion journalière et directeur général)
  • Director appointment, Alain Marlier (personne chargée de la gestion journalière et directeur général adjoint)
  • Power of attorney, El Djouhar Alexandra Rekaï
  • Power of attorney, Geneviève De Bue
  • Power of attorney, Serge Doris
  • +1 further facts in this act
13-07
NBB filing Annual accounts filed
fiscal year 2016 · full schema
03-02
State Gazette act Statutes amendment · Resignations & appointments
Name change2 facts ▸
  • Name change, PolyPeptide
  • Statutes amendment
24-01
State Gazette act Resignations: Rodolfo Jose Savitzky, Stefan Heinz Stoffel and Daniel Blättler
Appointments: Jane Salik, Daniel Lasanow and 2 others · Mandate compensation12 facts ▸
  • Shareholder decision, 03/01/2017
  • Director resignation, Rodolfo Jose Savitzky (director)
  • Director resignation, Stefan Heinz Stoffel (director)
  • Director resignation, Daniel Blättler (director)
  • Director appointment, Jane Salik (director)
  • Director appointment, Daniel Lasanow (director)
  • Director appointment, Jan Fuhr Miller (director)
  • Director appointment, Peter Nilsson (director)
  • Mandate compensation, Jane Salik
  • Mandate compensation, Daniel Lasanow
  • Mandate compensation, Jan Fuhr Miller
  • Mandate compensation, Peter Nilsson
2016
01-12
State Gazette act Resignation: Toralf Andrew Haag (director)
Appointment: Rodolfo Jose Savitzky (director) · Director discharge · Mandate compensation5 facts ▸
  • General meeting, 09/11/2016
  • Director resignation, Toralf Andrew Haag (director)
  • Director discharge, Toralf Andrew Haag (director)
  • Director appointment, Rodolfo Jose Savitzky (director)
  • Mandate compensation, Rodolfo Jose Savitzky
01-08
State Gazette act Reappointments: Serge Marie J Doris, Geneviève De Bue and 2 others
Appointments: Frédérique Marie Vogeleiser ep. Mutterer (directeur général) and Bert Irma V Variroye (directeur général adjoint) · Power of attorney14 facts ▸
  • Board meeting, 01/07/2016
  • Power of attorney, Eugénia Tsirimikos
  • Director reappointment, Serge Marie J Doris (director)
  • Director reappointment, Geneviève De Bue (director)
  • Director reappointment, Mireille Colette B. Leclercq (director)
  • Director reappointment, El-Djouhar Alexandra Rekai (director)
  • Power of attorney, Serge Marie J Doris
  • Power of attorney, Geneviève De Bue
  • Power of attorney, Mireille Colette B. Leclercq
  • Power of attorney, El-Djouhar Alexandra Rekai
  • Director appointment, Frédérique Marie Vogeleiser ep. Mutterer (directeur général)
  • Director appointment, Bert Irma V Variroye (directeur général adjoint)
  • +2 further facts in this act
20-06
State Gazette act Reappointments: Toralf Haag (director) and Stefan Heinz Stoffel (director)
Mandate compensation · Power of attorney8 facts ▸
  • General meeting, 17/05/2016
  • Director reappointment, Toralf Haag (director)
  • Director reappointment, Stefan Heinz Stoffel (director)
  • Mandate compensation, Toralf Haag
  • Mandate compensation, Stefan Heinz Stoffel
  • Power of attorney, Darie Robbrecht
  • Power of attorney, Jessica Lanzillotta
  • Power of attorney, BVBA Ad-Ministerie
10-06
NBB filing Annual accounts filed
fiscal year 2015 · full schema
08-02
State Gazette act Miscellaneous
Statutes amendment1 fact ▸
  • Statutes amendment
05-01
State Gazette act Resignations & appointments
Power of attorney1 fact ▸
  • Power of attorney, Ad-Ministerie SPRL
2015
11-12
State Gazette act Appointment: Klynveld Peat Marwick Goerdeler - KPMG SCRL (statutory auditor)
Permanent representative: Alexis Palm · Mandate term4 facts ▸
  • General meeting, 24/11/2015
  • Auditor appointment, Klynveld Peat Marwick Goerdeler - KPMG SCRL (statutory auditor)
  • Permanent representative, Alexis Palm
  • Mandate term, expire après l'Assemblée Générale des Associés relative aux comptes annuels du 31 décembre 2017 qui aura lieu en 2018
2014
03-09
State Gazette act Resignation: Stephan Kutzer (director)
Appointment: Daniel Blättler (director) · Director discharge · Mandate compensation5 facts ▸
  • General meeting, 09/07/2014
  • Director resignation, Stephan Kutzer (director)
  • Director discharge, Stephan Kutzer (director)
  • Director appointment, Daniel Blättler (director)
  • Mandate compensation, Daniel Blättler
15-04
State Gazette act Appointment: El Djouhar Alexandra Rekai (daily management delegate)
Reappointments: Gerieviève De Bue, Eugénia Tsirimikos and 2 others5 facts ▸
  • Director appointment, El Djouhar Alexandra Rekai (daily management delegate)
  • Director reappointment, Gerieviève De Bue (mandataire)
  • Director reappointment, Eugénia Tsirimikos (mandataire)
  • Director reappointment, Mireille Leclercq (mandataire)
  • Director reappointment, Serge Doris (mandataire)
19-02
State Gazette act Resignation: Arjen Vermeer (director)
Director discharge3 facts ▸
  • General meeting, 15/01/2014
  • Director resignation, Arjen Vermeer (director)
  • Director discharge, Arjen Vermeer (director)
2013
26-07
State Gazette act Resignations: James Leresche (délégué à la gestion journalière / directeur général) and Laurent Demoisy (mandat)
Appointments: Frédérique Vogeleisen (délégué à la gestion journalière / directeur général) and Bert Vanroye (directeur général adjoint) · Power of attorney11 facts ▸
  • Board meeting, 30/04/2013
  • Director resignation, James Leresche (délégué à la gestion journalière / directeur général)
  • Director appointment, Frédérique Vogeleisen (délégué à la gestion journalière / directeur général)
  • Director appointment, Frédérique Vogeleisen (délégué à la gestion journalière / directeur général)
  • Director appointment, Bert Vanroye (directeur général adjoint)
  • Power of attorney, Mireille Leclercq (mandataire spécial)
  • Power of attorney, Geneviève De Bue (mandataire spécial)
  • Power of attorney, Eugénia Tsirimikos (mandataire spécial)
  • Power of attorney, Serge Doris (mandataire spécial)
  • Director resignation, James Leresche (mandat)
  • Director resignation, Laurent Demoisy (mandat)
28-02
State Gazette act Permanent representatives: Michel Lange and Alexis Palm
Appointments: James Leresche (director) and Bert Vanroye (director)5 facts ▸
  • Board meeting, 15/01/2013
  • Permanent representative, Michel Lange
  • Permanent representative, Alexis Palm
  • Director appointment, James Leresche
  • Director appointment, Bert Vanroye
24-01
State Gazette act Capital & shares · Statutes amendment · Resignations & appointments
Capital increase · Capital decrease · Capital6 facts ▸
  • General meeting, 21/12/2012
  • Capital increase, €63.800.000
  • Capital decrease, €63.800.000
  • Capital, €40.000.000
  • Statutes amendment
  • Power of attorney, Clifford Chance LLP
2012
06-09
State Gazette act Resignation: Olivier Ludemann-Hombourger (délégué à la gestion journalière / directeur général adjoint)
Appointment: Bert Vanroye (délégué à la gestion journalière / directeur général adjoint) · Power of attorney12 facts ▸
  • Board meeting, 20/07/2012
  • Director resignation, Olivier Ludemann-Hombourger (délégué à la gestion journalière / directeur général adjoint)
  • Director appointment, Bert Vanroye (délégué à la gestion journalière / directeur général adjoint)
  • Director appointment, Bert Vanroye (délégué à la gestion journalière / directeur général adjoint)
  • Power of attorney, James Leresche
  • Power of attorney, Bert Vanroye
  • Power of attorney, Laurent Demoisy
  • Power of attorney, Geneviève De Bue
  • Power of attorney, Eugenia Tsirimikos
  • Power of attorney, Frédérique Mutterer
  • Power of attorney, Serge Doris
  • Power of attorney, Patrick Loosen
02-07
State Gazette act Appointment: Klynveld Peat Marwick Goedeler - KPMG SCRL (statutory auditor)
Permanent representative: Michel Lange3 facts ▸
  • General meeting, 15/05/2012
  • Auditor appointment, Klynveld Peat Marwick Goedeler - KPMG SCRL (statutory auditor)
  • Permanent representative, Michel Lange
28-03
State Gazette act Resignations & appointments
Power of attorney5 facts ▸
  • Board meeting, 15/02/2012
  • Power of attorney, Bert Vanroye
  • Power of attorney, Serge Doris
  • Power of attorney, Frédérique Mutterer
  • Power of attorney, Eugénia Tsirimikos
17-02
State Gazette act Appointment: Abraham Arjen Vermeer (director)
Mandate compensation3 facts ▸
  • General meeting, 16/01/2012
  • Director appointment, Abraham Arjen Vermeer (director)
  • Mandate compensation, Abraham Arjen Vermeer
2011
17-06
State Gazette act Reappointment: Toralf Haag (director)
2 facts ▸
  • General meeting, 17/05/2011
  • Director reappointment, Toralf Haag (director)
17-06
State Gazette act Resignations: Patrick Loosen, Olivier Ludemann-Hombourger and Pascal Brouyère
Appointments: James Leresche, Olivier Ludemann-Hombourger and Patrick Loosen7 facts ▸
  • Board meeting, 19/05/2011
  • Director resignation, Patrick Loosen (délégué à la gestion journalière et directeur général)
  • Director appointment, James Leresche (délégué à la gestion journalière et directeur général)
  • Director appointment, Olivier Ludemann-Hombourger (délégué à la gestion journalière et directeur général adjoint)
  • Director resignation, Olivier Ludemann-Hombourger (mandataire spécial)
  • Director resignation, Pascal Brouyère (mandataire)
  • Director appointment, Patrick Loosen (mandataire spécial)
2010
18-11
State Gazette act Resignations & appointments
Power of attorney4 facts ▸
  • Board meeting, 12/10/2010
  • Power of attorney, Olivier Ludemann-Hombourger
  • Power of attorney, Stephan Rosenberger
  • Power of attorney, Ewald Amherd
22-06
State Gazette act Resignation: Uwe Boehlke (director)
Appointments: Stephan Kutzer (director) and Stefan Stoffel (director)4 facts ▸
  • General meeting, 18/05/2010
  • Director resignation, Uwe Boehlke (director)
  • Director appointment, Stephan Kutzer (director)
  • Director appointment, Stefan Stoffel (director)
2009
18-05
State Gazette act Resignation: Seppe De Gelas (director)
Power of attorney8 facts ▸
  • Board meeting, 15/04/2009
  • Power of attorney, Frédérique Mutterer
  • Power of attorney, Seppe De Gelas
  • Power of attorney, Pascal Brouyère
  • Power of attorney, Eugenia Tsirimikos
  • Power of attorney, Ewaid Amherd
  • Power of attorney, Serge Doris
  • Director resignation, Seppe De Gelas
2008
02-06
State Gazette act Resignations & appointments
Power of attorney5 facts ▸
  • Board meeting, 30/04/2008
  • Power of attorney, James Leresche
  • Power of attorney, Ewald Amherd
  • Power of attorney, Philippe Simetin
  • Power of attorney, Marie-Hélène Brichard
2007
29-08
State Gazette act Capital & shares · Statutes amendment
Approval · Capital increase · Capital5 facts ▸
  • General meeting, 30/07/2007
  • Approval, rapports du conseil d'administration et de KPMG
  • Capital increase, €20.000.000
  • Capital, €40.000.000
  • Power of attorney, Clifford Chance LLP
18-06
State Gazette act Resignation: Lukas Utiger (director)
Appointment: Uwe Boehlke (director)3 facts ▸
  • General meeting, 15/05/2007
  • Director resignation, Lukas Utiger (director)
  • Director appointment, Uwe Boehlke (director)
04-06
State Gazette act Resignations & appointments
Power of attorney11 facts ▸
  • Board meeting, 20/05/2007
  • Power of attorney, Patrick Loosen
  • Power of attorney, Philippe Simetin
  • Power of attorney, Seppe De Gelas
  • Power of attorney, Marie-Hélène Brichard
  • Power of attorney, Pascal Brouyère
  • Power of attorney, Eugenia Tsirimikos
  • Power of attorney, Serge Doris
  • Power of attorney, Karl-Heinz
  • Power of attorney, Raphael Stucky
  • Power of attorney, Vincent Bille
2006
26-06
State Gazette act Resignations & appointments
Power of attorney · Joint representation10 facts ▸
  • Board meeting, 27/04/2009
  • Power of attorney, Patrick Loosen
  • Power of attorney, Philippe Simetin
  • Power of attorney, Seppe De Gelas
  • Power of attorney, Karl-Heinz Gratzel
  • Power of attorney, Raphael Stucky
  • Power of attorney, Marie-Helene Brichard
  • Power of attorney, Pascal Brouyere
  • Power of attorney, Vincent Bille
  • Joint representation, agissant deux par deux, soit avec un des délégués à la gestion journalière, soit avec un autre mandataire spécial
13-03
State Gazette act Appointments: Stéphane Mischler (daily management delegate) and Alain Scarso (daily management delegate)
3 facts ▸
  • Board meeting, 15/02/2006
  • Director appointment, Stéphane Mischler (daily management delegate)
  • Director appointment, Alain Scarso (daily management delegate)
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
45 of 45 acts read

Directors · office · real estate

Directors
19 directors, no change since 2023
Polypeptide Laboratories Holding (PPL) AB
Sole director · since 17-05-2023 · Legal entity · perm. rep.: Jens FRICKE
Current
El-Djouhar Alexandra Rekai
Personne chargée de la gestion journalière et directeur général adjoint · since 26-03-2014
Not recently confirmed
Peter Nilsson
Director · since 03-01-2017
Not recently confirmed
Bert Irma V Variroye
Directeur général adjoint · since 30-04-2013
Not recently confirmed
Frédérique Marie Vogeleiser ep. Mutterer
Directeur général · since 30-04-2013
Not recently confirmed
Not recently confirmed
13 other directors
Not recently confirmed
Not recently confirmed
Toralf Haag
Director · since 17-05-2011
Not recently confirmed
Eugénia Tsirimikos
Mandataire · since 26-03-2014
Not recently confirmed
M. Serge Doris
Mandataire · since 26-03-2014
Not recently confirmed
Mireille Leclercq
Mandataire · since 26-03-2014
Not recently confirmed
Mme Gerieviève De Bue
Mandataire · since 26-03-2014
Not recently confirmed
Frédérique Vogeleisen
Délégué à la gestion journalière / directeur général · since 01-05-2013
Not recently confirmed
Abraham Arjen Vermeer
Director · since 16-01-2012
Not recently confirmed
Patrick Loosen
Mandataire spécial · since 19-05-2011
Not recently confirmed
Stefan Stoffel
Director · since 18-05-2010
Not recently confirmed
Alain Scarso
Daily management delegate · since 10-02-2006
Not recently confirmed
Stéphane Mischler
Daily management delegate · since 10-02-2006
Not recently confirmed
17-05-2023 Polypeptide Laboratories Holding (PPL) AB: Appointed as Sole director
17-05-2023 Jan Fuhr MILLER: Resigned as Director
17-05-2023 Jens FRICKE: Resigned as Director
25-04-2023 Vincenzo MANCUSO: Resigned as Director
25-04-2023 Vincenzo MANCUSO: Resigned as Managing director and daily management delegate
Full history in the Timeline (71 changes) →See the board, name and seat on a given date →
Location & real-estate footprint
Registered office, Braine-l'Alleud · 2 establishment units since 2006
seat establishment All 2 establishment units on the map
Ground area
8.0 ha
Building footprint
2,404 m²
Volume, LiDAR
16,476 m³
2 parcels, Flanders, Wallonia · tallest building 11.8 m, ±3 floors. Linked by address, not a title deed.
2 establishment units
PolyPeptide
Chaussée de Tubize 297, 1420 Braine-l'AlleudManufacture of basic metals
since 20062.151.696.263
Jozef Huysmanslaan 53, 1651 Beersel
Warehousing and storage
since 20242.356.361.810
2 parcels
Flanders 1 (50%) Wallonia 1 (50%)
Parcel (capakey) Region Area Buildings Height / fl.
25743G0205/00T000 Wallonia 7.9 ha 1 · 1,824 m² 9.0 m · 3 fl.
23046C0254/02G002 Flanders 1,349 m² 1 · 580 m² 11.8 m · 2 fl.
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Statutory auditor

1 auditor
BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISESCurrent
Statutory auditor · represented by Rodrigo ABELS
15-05-2018 → present
Show 3 earlier auditors
Klynveld Peat Marwick Goedeler - KPMG SCRL
Statutory auditor · represented by Michel Lange
succeeded by Klynveld Peat Marwick Goerdeler - KPMG SCRL in 2015
02-07-2012 → 11-12-2015
Klynveld Peat Marwick Goerdeler - KPMG SCRL
Statutory auditor · represented by Alexis Palm
succeeded by KPMG Réviseurs d'Entreprises SC SCRL in 2018
11-12-2015 → 15-05-2018
KPMG Réviseurs d'Entreprises SC SCRL
Statutory auditor
15-05-2018 → 26-07-2018

Articles of association

Purpose
La recherche, la fabrication, l'achat, la vente et la transformation de tous ingrédients, matières ou produits chimiques et pharmaceutiques, purs, simples ou composés; ainsi que de…
Full purpose

La recherche, la fabrication, l'achat, la vente et la transformation de tous ingrédients, matières ou produits chimiques et pharmaceutiques, purs, simples ou composés; ainsi que de matières et produits similaires ou connexes. Elle peut également exercer toute activité d'ingénieur conseil, de bureau d'études, de conception ou réalisation d'appareils ou d'entreprises publiques ou privées - y compris l'organisation - rien excepté ni réservé. Elle peut plus généralement entreprendre toutes opérations de commerce, d'industrie et de finance, mobilières, immobilières, agricoles et minières, tant en Belgique qu'à l'étranger, se rattachant, soit directement, soit indirectement, aux dits objets. Elle peut s'intéresser par voie d'apport, de fusion, de souscription ou achat de titres ou droits sociaux, de participation ou de toute autre manière dans toutes entreprises dont l'objet se rattache directement ou indirectement à son industrie ou son commerce. A cet effet, la société peut collaborer et prendre part, ou prendre un intérêt dans d'autres entreprises, directement ou indirectement, de quelque manière que ce soit. La société peut donner caution tant pour ses propres engagements que pour les engagements de tiers, entre autres en donnant ses biens en hypothèque ou en gage, y compris son propre fonds de commerce. La société peut d'une façon générale accomplir toutes opérations commerciales, industrielles, financières, mobilières ou immobilières se rapportant directement ou indirectement à son objet ou qui seraient de nature à en faciliter la réalisation.

Structure & network

Connections & network

2 connected companies
Depth

The connected companies are in the list below.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, scroll to zoom.
Linked via shared directors

Capital and shareholders

Shareholders according to the acts
After the capital increase act of 29-08-2007 ↗
  • Lonza AG

The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years
  1. 29-12-2021 Capital stated in the act · 40,000,000 EUR · 40,000 shares
  2. 24-01-2013 Capital increase of 63,800,000 EUR · to 103,800,000 EUR · in kind
  3. 24-01-2013 Capital reduction of 63,800,000 EUR · to 40,000,000 EUR · to absorb losses
  4. 29-08-2007 Capital increase of 20,000,000 EUR · to 40,000,000 EUR · 20,000 new shares · in kind

Recognitions · licences · registrations

Food safety, FASFC

1 site
Braine-l'Alleud2.151.696.263
1 permission
Toelating · Andere grootkeuken (bereiding - distributie maaltijden) · since 01-02-2008

Legal Entity Identifier

894500XRM0N1353TSE52
live in the LEI register

Similar companies · same sector, comparable size

Of 148 companies in sector 21100 we hold annual accounts for 108. 11 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPublic limited company
Founded14-02-2006
Fiscal year end31-12
Activities, NACEBEL 2025
21100Manufacture of basic pharmaceutical products and pharmaceutical preparations
20130Manufacture of chemicals and chemical products
20140Manufacture of chemicals and chemical products
20200Manufacture of chemicals and chemical products
20590Manufacture of chemicals and chemical products
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
Contact
E-mail PPBE0-HR@polypeptide.comBraine-l'Alleud
Phone +3223862909Braine-l'Alleud

Scores and ratios are computed by Checked and are not a credit decision.